With FDA nod on Uceris, Santarus puts out 'help wanted' sign for sales reps

Now that Santarus ($SNTS) has FDA approval in hand for its ulcerative colitis remedy Uceris, the company plans to staff up on the sales side, with 85 hires for its field force. Report

Suggested Articles

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.

Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.